J&J's Zytiga slashes death risk by 38% in earlier-stage prostate cancer patients

3rd June 2017 Uncategorised 0

Johnson & Johnson may soon be able to move prostate cancer med Zytiga into an earlier disease stage, thanks to game-changing new data that rolled out Saturday at ASCO.

More: J&J's Zytiga slashes death risk by 38% in earlier-stage prostate cancer patients
Source: fierce